Business
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
On-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio
About this update from Vor Biopharma Inc.
[{"type":"text","content":"On-track for trem-cel + Mylotarg™ and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update. “We are pleased with the progress we have made with enrollment of both the trem-cel + Mylotarg and VCAR33ALLO clinical trials during the quarter,” said Dr. Robert Ang, Vor Bio’s President and Chief Executive Officer. “Every year, thousands of patients with AML and MDS relapse post-transplant with no safe and effective treatment options. Our approach of shielded transplants may provide the first opportunity to deliver curative treatments post-transplant. We look forward to our next clinical update in the second half of this year.” Corporate Updates Trem-cel trial continues to enroll rapidly and patients are receiving Mylotarg at the third dose level 21 patients have been dosed with trem-cel and patients are now receiving the third dose level of Mylotarg at 2.0 mg/m2. The next data update is expected in the second half of 2024 and will include engraftment and hematologic protection data, and additional Mylotarg pharmacokinetic analyses. Several patients have been followed out for more than one year, and the Company also expects to provide a clinical update on these patients.Trem-cel is a shielded transplant in development for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), in which healthy transplant donor cells are genetically engineered by removing CD33, with the potential to shield healthy cells and enable targeted therapies post-transplant such as Mylotarg and CAR-T therapy. Continued progress with VCAR33ALLO Several patients have been dosed with VCAR33ALLO in the VBP301 study with enrollment continuing, and initial data is still expected in the second half of 2024.VBP301, a Phase 1/2, multicenter, open-label, first-in-human study of VCAR33ALLO, is a transplant donor-derived anti-CD33 CAR-T cell therapy for patients with AML who have relapsed following a standard-of-care or trem-cel transplant. Upcoming Milestones Trem-cel clinical data update expected in the second half of 2024VCAR33ALLO clinical data update expected in the second half of 2024 Second Quarter 2024 F...